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Abstract 
Lung cancer has become the leading killer cancer worldwide, due to late diagnosis and lack of 
efficient anticancer drugs. We have recently described novel natural-derived tambjamine analogues 
that are potent anion transporters capable of disrupting cellular ion balance, inducing acidification of 
the cytosol and hyperpolarization of cellular plasma membranes. Although these tambjamine 
analogues were able to compromise cell survival, their molecular mechanism of action remains 
largely unknown. Herein we characterize the molecular cell responses induced by highly active 
indole-based tambjamine analogues treatment in lung cancer cells. Expression changes produced 
after compounds treatment comprised genes related to apoptosis, cell cycle, growth factors and its 
receptors, protein kinases and topoisomerases, among others. Dysregulation of BCL2 and 
BIRC5/survivin genes suggested the apoptotic pathway as the induced molecular cell death 
mechanism. In fact, activation of several pro-apoptotic markers (caspase 9, caspase 3 and PARP) and 
reversion of the cytotoxic effect upon treatment with an apoptosis inhibitor (Z-VAD-FMK) were 
observed. Moreover, members of the Bcl-2 protein family suffered changes after tambjamine 
analogues treatment, with a concomitant protein decrease towards the pro-survival members. 
Besides this, it was observed cellular accumulation of ROS upon compound treatment and an 
activation of the stress-kinase p38 MAPK route that, when inhibited, reverted the cytotoxic effect of 
the tambjamine analogues. Finally, a significant therapeutic effect of these compounds was observed 
in subcutaneous and orthotopic lung cancer mice models. Taken together, these results shed light on 
the mechanism of action of novel cytotoxic anionophores and demonstrate the therapeutic effects 
against lung cancer. 
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Introduction 
Lung cancer (LC) is the most common cancer that threatens human health, accounting for more than 
19% of all cancer deaths in 2012 (1). Health systems have standardized clinical procedures for 
treating LC patients being surgery, conventional platinum-based doublet chemotherapy (e.g. 
carboplatin/taxol or pemetrexed) and targeted therapies (e.g. erlotinib and other novel anti-EGFR 
mutated receptors) the main options (2). Nevertheless, conventional chemotherapy shows low 
efficacy with important treatment-related toxicity. Therefore, development of novel efficient drugs is 
urgently needed. In this regard, the diversity of marine environment provides an extraordinary array 
of biologically active metabolites for the development of new anticancer therapeutics. In late 2007, 
trabectedin (Yondelis, PharmaMar) became the first marine anticancer drug to be approved in the 
European Union (3). Over the past decade, there has been an increase in the number of new 
anticancer lead compounds from marine life that have entered in human clinical trials (4). 
Nowadays, more than 592 marine compounds are included in the pipeline of modern 
pharmaceuticals discovery programs, showing promising antitumor and cytotoxic activities (5). The 
natural alkaloids tambjamines were originally isolated from marine invertebrates including 
bryozoans, nudibranchs and ascidians (6). Tambjamines possess a wide spectrum of pharmacological 
properties and seem to be involved in the chemical defense mechanisms of the organisms from 
which they derive (6). Structurally, these alkaloids are characterized by a 4-methoxybipyrrole moiety 
shared by other families of natural products such as the prodiginines (7). It is already well known that 
prodiginines have pro-apoptotic activity against several cancer cells including lung, breast and 
hematopoietic, showing the ability to overcome the multidrug resistance phenotype (8-10). 
Tambjamines, like prodiginines, are very efficient anion exchangers (anionophores) in model 
liposomes promoting both chloride and bicarbonate transport, which are the most abundant anions 
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in biological environments (7, 11, 12). Their anionophoric activity has an impact on cellular ion 
homeostasis, intracellular pH levels and cell survival (11, 12). Recently, we have demonstrated that 
synthetic tambjamine analogues induce intracellular pH acidification and cytotoxicity in LC cells and 
human-derived cancer stem cells (CSCs), and how this is related to their anion transport abilities 
(13). Cancer stem cells are defined as immortal cells within a tumor that have the ability to 
perpetuate themselves through self-renewal, to spawn differentiated progeny (non-CSCs) and 
contribute to acquired chemotherapy resistance in cancer (14). Moreover, their facilitated transport 
activity triggers hyperpolarization of plasma membrane in LC cells and differentiation and cell death 
in CSCs, leading to an effective elimination of this tumor subpopulation (13).  
Although substantial work has already been done concerning chemical characterization of 
tambjamines and the impact of their anionophoric properties in cell survival and differentiation, their 
molecular mechanism of action still remains unclear. Here, we report a detailed study of how cancer 
cells respond to several highly active indole-based tambjamine analogues at the transcript and 
protein levels. Moreover, we have elucidated the molecular cell death mechanism induced by these 
compounds as well as assessed their therapeutic effect in vivo in several LC mouse models. 
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Materials and Methods 
Compounds synthesis. Compounds 1-11 were synthesized by condensation of , 5-(1H-indole-2-yl)-3-
methoxy-1H-pyrrole-2-carbaldehyde with the appropriate amine using acetic acid as catalyst. 
Detailed synthetic procedures and characterization data are provided in the supplementary 
information (S1-S36). 
 
Cell lines and culture conditions. The human LC cell lines, adenocarcinoma (A549, CCL185™), 
squamous carcinoma (SW900, HTB59™), small cell carcinoma (DMS53, CRL2062™) and large cell 
carcinoma (H460, HTB177™) were obtained from American Tissue Culture Collection (ATCC, 
Manassas, VA, USA). All cell lines were tested and authenticated by ATCC using short tandem repeat 
analysis. All cell lines were cultured (passage number 10-25) following ATCC recommended media 
(Biological Industries, Beit Haemek, Israel) supplemented with 10% heat-inactivated fetal bovine 
serum (FBS; Gibco, Thermo Fisher Scientific Inc. Waltham, MA, USA), 100 U/ml penicillin, 100 µg/ml 
streptomycin, and 2 mM L-glutamine, all from Biological Industries. Cells were grown at 37°C in a 
humidified incubator (Thermo Fisher Scientific Inc.) with 5% CO2 atmosphere and were mycoplasma-
free. 
 
Establishment of LC patient-derived primary cultures. This protocol was approved by the local Ethics 
Committee (PR003/13) and, upon signed informed consent; fresh human LC tissues were obtained 
from 20 patients with primary LC (age range 55–81 years) undergoing lobectomy or 
pneumonectomy at Bellvitge University Hospital from April 2013 to March 2014. Histological 
diagnosis was determined based on microscopic features of carcinoma cells. Freshly obtained tumor 
tissue (within 1–2 hours after surgical removal) was washed in RPMI-1640 medium (Biological 
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Industries) containing 100 U/ml penicillin and 100 µg/ml streptomycin. Blood vessels and connective 
tissue were carefully removed and the cancerous area was then minced into small pieces less than 1 
mm3 using a scalpel. Chopped tissue was resuspended in RPMI-1640 medium containing collagenase 
II (Sigma-Aldrich, Merck KGaA, Darmstadt, Germany) at a concentration of 200 U/ml and digested for 
2–4 hours at 37°C in a humidified incubator. The enzymatic digestion was stopped when most of the 
cells were in a single cell suspension. Following two washes in RPMI-1640, cells were transferred into 
standard tissue culture coated flasks (TPP, Trasadingen, Switzerland) and cultured in the Defined 
Keratinocyte-Serum Free Medium (DK-SFM, Gibco, Thermo Fisher Scientific Inc.) supplemented with 
100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, 20 ng/ml EGF (Sigma-Aldrich, Merck 
KGaA), 10 ng/ml basic-FGF (Sigma-Aldrich, Merck KGaA), 2% B27 (Gibco, Thermo Fisher Scientific 
Inc.) and 0.25 mg/ml amphotericin B (Sigma-Aldrich, Merck KGaA). All LC patient-derived cultures 
were maintained at 37°C in a humidified incubator (Thermo Fisher Scientific Inc.) with 5% CO2. 
Culture medium was changed every 2–3 days. Cells were passaged after detachment with 
TrypLETMExpress (Invitrogen, Thermo Fisher Scientific Inc.), when the cells reached 80–90% 
confluence. We were able to establish two LC primary cultures (PC), one derived from an 
adenocarcinoma tumor (PC#8) and the other derived from a squamous cell carcinoma (PC#13), 
which were used for subsequent viability assays. LC patient-derived PC were characterized by 
immunofluorescence, according to their epithelial or mesenchymal biomarker expression, using 
cytokeratin-8 (Cat#IF13, Oncogene, Merck KGaA) for the epithelial phenotype and vimentin 
(Cat#3932, Cell Signaling Technology Inc., Danvers, MA, USA) for the mesenchymal phenotype. 
 
Cell viability assays. Cell viability was evaluated using the methylthiazoletetrazolium (MTT, Sigma-
Aldrich, Merck KGaA) colorimetric assay. Cells were harvested (104 cells/well) in 96-well plates in a 
final volume of 100 µl and allowed to grow overnight. At the following day, vehicle solution (DMSO, 
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Sigma-Aldrich, Merck KGaA) or experimental compounds were added at a single point (10 µM) or at 
different ranging concentrations (0.8-100 µM for compounds 1 and 2, 1.6-200 µM for cisplatin) to 
the assay plate. Cells were incubated for 24 hours and after the treatment period, 10 µl of MTT (5 
mg/ml) were added and the plates were incubated for 4 hours at 37°C. Crystals were dissolved in 
100 µl of DMSO, after which the reading was taken spectrophotometrically at 570 nm using a multi-
well plate reader (Multiskan FC, Thermo Fisher Scientific Inc.). Cell viability and inhibitory 
concentration (IC) values were obtained using GraphPad Prism V5.0 for Windows (Graphpad 
Software, San Diego, CA, USA). All data are shown as the mean value ± standard deviation (S.D.) of 
three independent experiments. Statistical analysis (one-way ANOVA) was carried out with the 
Statgraphics plus 5.1. Statistical package (Manugistics, Rockville, MD, USA). Cisplatin was bought 
from Alfa Aesar (Thermo Fisher Scientific Inc.). 
 
Gene expression analysis. The A549 cell line was seeded at a density of 2x105 cells in 60 mm plates 
and allowed to grow for 24 hours. Subsequently, cells were exposed to the IC50 of the tambjamine 
analogues 1 or 2 for 6 or 16 hours. Total RNA was extracted and purified using the column-based 
RNeasy Mini Kit (QIAGEN, Hilden, Germany), according to the manufacture’s protocol. Total RNA 
concentration and purity was checked in a nano spectrophotometer (Implen GmbH, München, 
Germany) and integrity was analyzed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa 
Clara, CA, USA). For the reverse transcription, 1 μg of total RNA was used for cDNA synthesis using a 
mixture of random hexamers and oligo-dT primers and following the RT2 First Strand Kit protocol 
(QIAGEN). The Human RT2 RNA Quality Control PCR Array (PAHS-999ZA format A, QIAGEN) was used 
to assess the cDNA quality and to check for genomic DNA contamination in an ABI PRISM 7700 
Sequence Detection System (Applied Biosystems, Thermo Fisher Scientific Inc.). For gene expression 
analysis, cDNAs of control and treated cells were mixed with RT2 SYBR ROX mastermix (QIAGEN) and 
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dispensed in the RT2 Profiler PCR Array of Human Cancer Drug Targets (PAHS-507A format E, 
QIAGEN). After 2 minutes centrifugation at 300 g, the array was placed in an ABI PRISM 7900HT real-
time PCR system (Applied Biosystems, Thermo Fisher Scientific Inc.) and the analysis was carried out 
according to manufacture’s instructions. Dissociation curves (melting curves) were carefully analyzed 
using SDS software v2.3 and RQ Manager v1.2 (both from Applied Biosystems, Thermo Fisher 
Scientific Inc.) in order to choose only the highly specific reaction products in the downstream 
analysis. The threshold cycle (CT) values obtained were analyzed in QIAGEN Data Analysis Center 
(QIAGEN) to retrieve the fold-regulation values for each gene. The network of most altered genes 
upon compounds treatment was produced in Cytoscape open-source software (Cytoscape 
Consortium, San Diego, CA, USA) (15) with data extracted from Gene Network Central (GNC-Pro, 
QIAGEN). 
 
Western blot analysis. A549 cells were seeded in 100mm culture plates (106 cells) and allowed to 
grow for 24 hours. Afterwards, they were exposed to compounds 1, 2 (IC25, IC50 and IC75 values) or 3 
(10 µM) for 24 hours. Total protein extracts were obtained from cells by the addition of lysis buffer 
containing 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, 50 mM sodium fluoride, 40 mM β-
glycerophosphate, 200 μM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride and 
protease inhibitor cocktail (Roche Diagnostics, Basel, Switzerland) in 1X PBS. Protein concentration 
was determined by BCA protein assay (Pierce, Thermo Fisher Scientific Inc.) using bovine serum 
albumin (BSA, Pierce, Thermo Fisher Scientific Inc.) as a standard. For Western blot analysis, 30 μg of 
protein extracts were first separated by SDS-polyacrylamide gel electrophoresis and transferred to 
Immobilon-P polyvinylidene difluoride (PVDF) membranes (EMD Millipore, Merck KGaG). 
Membranes were blocked in either 5% dry milk or BSA, both diluted in TBS–Tween (50 mM Tris–HCl 
pH 7.5, 150 mM NaCl, 0.1% Tween-20) for 1 hour and then incubated overnight with primary 
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antibodies, according to the manufacturer’s instructions. Antibodies were obtained from the 
following sources: anti-Caspase-3 (Cat#9662), anti-cleaved-Caspase-3 (Cat#9661), anti-Caspase-9 
(Cat#9502), anti-PARP1 (Cat#9542), anti-Bak (Cat#6947), anti-Bax (Cat#2772), anti-Bcl-2 (Cat#4223), 
anti-Mcl-1 (Cat#4572), anti-phospho-p38 MAPK (Thr180/Tyr182, Cat#4511), anti-p38 MAPK 
(Cat#9212) and anti-Survivin (Cat#2808), were all obtained from Cell Signaling Technology Inc.; anti-
Actin (I-19, Cat#sc-1616) from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA) and anti-Vinculin 
(Cat# V-4505) from Sigma-Aldrich, Merck KGaA. Antibody binding was detected with goat anti-
mouse IgG-HRP (Cat#sc-2005), goat anti-rabbit IgG-HRP (Cat#sc-2004) or donkey anti-goat IgG-HRP 
(Cat#sc-2020) all from Santa Cruz Biotechnology Inc. and the ECL detection kit (Amersham, GE 
Healthcare, Little Chalfont, UK). Actin or vinculin were used as gel loading controls. The results 
shown are representative of Western blot data obtained from at least three independent 
experiments. Images were captured on an Image Quant LAS 500 (GE Healthcare) and band 
densitometries were retrieved using the Image Studio Lite software (v5.0, Li-COR Biosciences, 
Lincoln, NE, USA). 
 
Inhibitor assays. Determination of viable cells (A549 cell line) after different inhibitors treatment was 
performed using the dual DNA intercalating fluorescent dyes kit MUSE™ Cell Count & Viability Assay 
(EMD Millipore, Merck KGaG). In brief, 2 x 105 cells/well in DMEM medium were seeded in a 6 well-
plate. After 24 hours, tambjamine analogues 1 and 2 at higher IC75 value were added, and incubated 
for 6 hours in a 5% CO2-cell culture incubator (Thermo Fisher Scientific Inc.). A pan-caspases inhibitor 
(Z-VAD-FMK; BD Bioscience, Franklin Lakes, NJ, USA) or a p38 MAPK inhibitor (SB202190; Cell 
Signaling Technology Inc.) was added at 20 and 30 µM respectively, 2 hours before compound 1 or 2 
exposure. Afterwards, cells were collected and were incubated with the Cell Count & Viability 
reagent for 5 minutes. Viability of treated cells was analyzed using the flow cytometry based MUSE™ 
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Cell Analyzer (EMD Millipore, Merck KGaA) according to the manufacture’s protocol. Viability was 
calculated as a percentage related to control cells and results shown were obtained from at least 
three independent experiments. Statistical analysis (one-way ANOVA) was carried out with the 
Statgraphics plus 5.1. Statistical package (Manugistics). 
 
Evaluation of reactive oxygen species (ROS) formation. Quantitative measurements of ROS in A549 
cells were performed using the MUSE™ Oxidative Stress Kit (EMD Millipore, Merck KGaG), based on 
dihydroethidium (DHE), a well characterized reagent that has extensively been used to detect 
reactive oxidative species in cellular populations. In brief, 2 x 105 cells/well in DMEM medium were 
seeded in a 6 well-plate. 24 hours after seeding, tambjamine analogues 1 and 2 at higher IC75 value 
were added, and incubated for 6 hours in a 5% CO2-cell culture incubator (Thermo Fisher Scientific 
Inc.). A positive control, named tert-Butyl hydroperoxide (TBHP, Sigma-Aldrich, Merck KGaA) was 
used at 2.5 mM for 2 hours, and the non-transporter tambjamine analogue (compound 3) was used 
as a negative control at 10 µM for 6 hours. Afterwards, cells were harvested and processed with the 
Oxidative Stress kit according to the manufacture’s protocol. The percentage of ROS positive and 
negative cells was calculated and results shown were obtained from at least three independent 
experiments. Statistical analysis (one-way ANOVA) was carried out with the Statgraphics plus 5.1. 
Statistical package (Manugistics). 
 
In vivo evaluation of indole-based tambjamine-analogues therapeutic effect. For the purpose of this 
article, two murine models have been designed: the subcutaneous and the orthotopic model 
systems. 5-weeks-old female Crl:NU-Foxn1nu mice strain (Envigo, Huntingdon, UK) were used in this 
study. All animal studies were performed in accordance with the guidelines approved by the 
Institutional Animal Care and Use Committee (IACUC). To generate the subcutaneous xenograft 
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model, mice were subcutaneously implanted with 4.5 x 106 DMS53 cells suspended in a 1:1 solution 
of RPMI-1460:Matrigel (BD Bioscience). For the orthotopic model, subcutaneous xenografts of 
DMS53 in exponential growth from three different animals were aseptically isolated and placed at 
room temperature in DMEM supplemented with 10% FBS plus 50 U/ml penicillin and 50 mg/ml 
streptomycin and the surgical resection tumors were implanted in Crl:NU-Foxn1nu mice following 
previously reported procedures (16, 17). Briefly, mice were anesthetized with a continuous flow of 
1% to 3% isoflurane/oxygen mixture (2 L/minutes) and subjected to right thoracotomy. Mice were 
situated in left lateral decubitus position and a small transverse skin incision (around 5 to 8 mm) was 
made in the right chest-wall. Chest muscles were separated by a sharp dissection and costal and 
intercostal muscles were exposed. An intercostal incision of 2-4 mm on the third or fourth rib on the 
chest-wall was made and a small tumor piece of 2-4 mm3 was introduced into the chest cavity. The 
tumor specimen was deposited between the second and the third lung lobule. Next, the chest-wall 
incision was closed with surgery staples, and finally chest muscles and skin were closed. Mice were 
inspected twice a week, and monitored for the presence of breathing problems.  
Mice bearing homogeneous subcutaneous tumors (approximately 150-200 mm3) were randomly 
allocated to three treatment groups (n=7/treatment). For DMS53 orthotopic derived model, mice 
were randomly allocated (n=6/treatment) and the treatment started 30 days after tumor 
implantation. Compounds 1 and 2 were diluted in 7.5% DMSO/0.8% Tween-80. All treatments were 
intraperitoneally administrated at a dose of 6 mg/kg in alternating days during 20 days. Tumor 
growth was recorded 2 to 3 times per week starting from the ﬁrst day of treatment (day 0) and 
tumor volume (in mm3), estimated according to the formula V ¼ (ab2)/2, (a: length or biggest 
diameter; b: width or smallest diameter). After the final dose the treatment, animals were sacrificed 
and tumors were dissected out and weighed. 
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Liver and kidney samples were fixed in 4% paraformaldehyde overnight, embedded in paraffin, and 
cut into sections (5 µm). Paraffin-embedded sections were deparaffinized in xylene and gradually 
rehydrated for hematoxylin and eosin staining. Stained liver and kidney sections were gradually 
dehydrated and mounted for hepatotoxicity and nephrotoxicity examination, respectively. 
 
Results 
Indole-based tambjamine analogues are cytotoxic against LC cells. 
To measure the inhibitory effect of novel tambjamine analogues (1-11; supplementary Fig. S1) on 
tumor cell proliferation, we have first performed a single-point MTT assay at 10 µM in four 
commonly used LC cell lines (A549, DMS53, SW900 and H460). After 24 hours of treatment, most of 
the compounds showed significant cell viability decrease, being compounds 1 and 2 the most 
promising anticancer agents (Fig. 1A). Then, half-maximal inhibitory concentration (IC50) values of the 
selected compounds were calculated in the same cell lines as well as in both adenocarcinoma and 
squamous patient-derived PC (Fig. 1B and Supplementary Fig. S37 and S38). The two selected 
compounds had similar potency against all the cell lines in the study, showing IC50 values below 
10µM. When compared with cis-diamminedichloroplatinum (II) (CDDP), commonly known as 
cisplatin, the standard chemotherapeutic agent used for LC treatment in the clinic, the IC50 values of 
this compound were all much higher than the ones of compounds 1 and 2. Interestingly, LC patient-
derived PC were more sensitive to our compounds, showing IC50 values below 5 µM while for 
cisplatin they were higher than 45 µM (Fig. 1B). This IC50 value for cisplatin is in accordance with 
published data (18, 19). Therefore, the selected tambjamine analogues displayed better cytotoxic 
activity against a panel of LC cell lines and PC than the current clinical standard treatment. 
 
Indole-based tambjamine analogues alter the expression of several cellular key genes. 
13 
 
To identify gene expression changes at the cellular level we have used a profiler array consisting of 
84 genes that are known cancer drug targets. The selected compounds 1 and 2 were tested in the 
adenocarcinoma cell line A549 at their respective IC50 values during two incubation periods (6 and 16 
hours). Both compounds have produced changes in several genes from diverse functional groups 
(Table 1). In general, the observed alterations (higher than 1.5 fold-regulation in at least 2 
conditions) were more evident at 16 hours with a clear tendency to genes down-regulation. In total 
26 genes were modulated, in which 20 were down-regulated by compounds 1 or 2 exposure. Down-
regulated genes included those related to: apoptosis, cell cycle, growth factors and receptors, 
protein kinases, topoisomerases, to name a few. Especially relevant for cell viability were genes 
related to cell death like the anti-apoptotic BLC2 (B-cell lymphoma 2) and the inhibitor of apoptosis 
(IAP) family member BIRC5/Survivin, as well as those related to cell cycle (e.g. CDK1 and CDK2). The 
remaining 6 genes were up-regulated and related to drug metabolism, protein kinases, transcription 
factors, cathepsins and heat shock proteins (Table 1). Concerning genes that are altered more than 3 
fold-regulation in at least 2 conditions, we have obtained CDC25A, FIGF/VEGFD, IGF1, NFKB1 and 
PTGS2/Cox-2. Six randomly selected genes were re-confirmed by another methodology 
(Supplementary Table S1 and Fig. S39). Similar results were obtained using another LC cell line from 
squamous carcinoma SW900 (77% gene match, Supplementary Table S2), suggesting that they may 
be implicated in tambjamine mechanism of action. Interestingly, three genes that were previously 
altered more than 3-fold in A549 cell line (FIGF, IGF and NFKB1) were not altered, IGF and NFKB1 or 
inversely regulated, FIGF, in the SW900 cell line. We further analyzed the altered genes using 
protein-protein interaction data and functional data extracted from Gene Network Central (GNC-Pro, 
QIAGEN). The results showed that compounds-modulated genes formed a highly connected network 
(Fig. 2), suggesting that these genes work as a functional module at the molecular level. The network 
also showed that NFKB1 and TP53 are hubs (densely connected nodes) which integrate signals from 
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the other nodes. Although these genes are hubs in our system, we did not observe any consistent 
transcriptional change in both cell line models.  
 
Indole-based tambjamine analogues induce apoptosis in lung cancer cells. 
Since we have obtained alterations in genes related to apoptosis and cell cycle and these processes 
are deeply involved in cell viability we checked if these mechanisms are activated in our cellular 
model. We were unable to detect any cell cycle arrest for either compounds tested, whereas 
cisplatin produced the well-documented G2/M phase arrest (Supplementary Fig. S40) (20). To 
elucidate if apoptosis is the molecular mechanism of cell death induced by these compounds, the 
expression levels of apoptosis-related proteins were analyzed by Western blot, since a decrease in 
the anti-apoptotic proteins Bcl-2 and survivin was detected in the gene expression array. The 
adenocarcinoma cell line A549 was treated with compounds 1 or 2 at the IC25, IC50 and IC75 
concentrations for 24 hours. The results showed that, at higher concentrations, compounds 
activated the proteolysis of both initiator pro-caspase-9 (CASP9 gene) and executioner pro-caspases-
3 (CASP3 gene) (Fig. 3a). Moreover, activation of the final apoptotic executioner PARP was also 
induced. Similar results were also obtained in the small cell carcinoma cell line DMS53 
(Supplementary Fig. S41). In addition, we checked the levels of the apoptotic complexes Bak/Mcl-1 
(BAK/MCL1 genes) and Bax/Bcl-2 (BAX/BCL2 genes). The pro-apoptotic effectors of the mitochondrial 
pathway (Bak and Bax) showed an increase in their protein levels after 24 hours treatment. On the 
contrary, Mcl-1 and Bcl-2 that are pro-survival members of the Bcl-2 family of proteins, presented a 
decrease on their protein levels after treatment (Fig. 3a-3c). The results for Bcl-2 protein expression 
corroborated the gene expression decrease previously observed in the profiler array (Table 1). Also 
in accordance with those results, down-regulation of the key oncogene BIRC5/Survivin was observed 
at the protein level by Western blot. A549 cells treated with compounds 1 or 2 (IC25, IC50 and IC75) 
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during 24 hours showed a dose-dependent decrease of survivin, indicating that this protein might 
play an important role on the cell death fate after compounds exposure (Fig. 3a).  
To further investigate the involvement of caspases activation on compounds-mediated apoptosis, 
A549 cells were treated 2 hours with a broad-spectrum caspase inhibitor, Z-VAD-FMK, and then with 
compounds 1 or 2 for 6 hours. Cell viability was then assessed by flow cytometry and results showed 
that the decrease in cell viability induced by compounds treatment was significantly reversed by the 
pan-caspase inhibitor Z-VAD-FMK (Fig. 3d), corroborating that apoptosis is involved in compounds-
induced cell death. 
 
Cytotoxic effect of compounds is triggered via a ROS-activated stress kinase pathway. 
The unbalance of ionic homeostasis produced by tambjamine analogues (13), could be initiating ROS 
production. Therefore, we tested whether compounds 1 and 2 could promote ROS accumulation in 
cells. Interestingly, after 6 hours treatment with compounds 1 or 2 (at higher IC75 value) there is a 
significant ROS formation compared with the non-treated condition or when the non-transporter 
tambjamine analogue (compound 3) is used (Fig. 4a). The effect of compounds is similar to the 
commonly used ROS stressor TBHP. The p38 MAPK signaling is one of the stress sensor pathways 
downstream of ROS formation that plays an essential role in inflammation, cell differentiation, 
growth and death. Thus, we have investigated by Western blot the phosphorylation of p38 MAP 
kinase after treatment with indole-based tambjamine analogues 1, 2 or 3 in A549 cells. After 24 
hours treatment with compounds 1 or 2 (IC25, IC50 and IC75), p38 MAPK (MAPK14 gene) 
phosphorylation increased in a dose response manner without any alteration in the total protein 
expression levels (Fig. 4b). Conversely, compound 3 (non-transporter) had no effect on the p38 
MAPK activation. The ROS inducer TBHP was shown before to also activate the p38 MAPK pathway 
(21). To further investigate whether activation of p38 MAPK was related to cell death, A549 cells 
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were pretreated with the p38 MAPK inhibitor SB202190 (30 µM) for 2 hours before compounds 
treatment. A significant reversion of cell death induced by compounds 1 and 2 was observed upon 
inhibitor pre-treatment, which indicates that compounds-mediated cell death is upstream regulated 
by the p38 MAPK signaling pathway (Fig. 4c).  
 
Therapeutic effect on in vivo mice models. 
To corroborate the anticancer activity of the indole-based tambjamine-analogues seen in several LC 
cell lines and patient-derived PC, we evaluated the therapeutic effect of compounds 1 and 2 in 
established DMS53 human small cell lung carcinoma growing subcutaneous and orthotopically in 
nude mice models. The DMS53 cell line was selected for their ability to grow well in the flank (for 
subcutaneous model) and in the lung (for orthotopic model) after cell inoculation. Mice bearing 
DMS53 xenografts were treated with compounds 1 or 2 (6 mg/kg in saline with 7.5% of DMSO/0.8% 
Tween-80) or vehicle control (7.5% of DMSO/0.8% Tween-80) in alternating days during 20 days. As 
shown in Figures 5a and 5b, compound 2 produced a significant decrease in tumor growth in 
subcutaneous models. Furthermore, treatment with compound 2 significantly (p < 0.05) reduced LC 
tumor progression in the orthotopic lung model (Fig. 5c). Importantly, as a single agent the 
treatment with compounds 1 or 2 did not produce any obvious toxicity (hepatotoxicity and 
nephrotoxicity, Fig. 5d), diarrhea or significant body weight loss (Supplementary Fig. S42). 
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Discussion 
Chemotherapeutic agents based on natural compounds are a potent source of anti-cancer drugs. 
Tambjamine analogues of natural compounds tambjamines have already demonstrated a good 
pharmacological activity and to have remarkable anti-cancer effects (6, 7, 11-13). In this study, we 
analyzed the cytotoxic effect and consequent induced cell death and elucidated the molecular 
mechanism of action of novel synthesized indole-based tambjamine analogues in LC cells. We have 
observed a significant cytotoxic effect (less than 10 µM at 24 h) of the selected compounds in several 
LC cell lines. Moreover, the selected compounds showed IC50 values remarkably lower than cisplatin, 
the main chemotherapeutic agent used in the treatment of LC patients. 
We have recently demonstrated how tambjamine analogues are able to alter the plasma membrane 
potential and decrease the intracellular pH in the A549 lung adenocarcinoma cell line (13). Changes 
in the ion homeostasis of the plasma membrane potential have already been associated with 
apoptosis-induced cell death in several cell types (S49, Jurkat, HL60, and thymocytes) (22, 23). These 
observations, in addition to our transcriptomic results and the failure to arrest cell cycle, led us to 
further investigate the molecular events related to the apoptotic process after cell treatment with 
these compounds. 
The mitochondrial apoptotic pathway is closely regulated by the dynamic equilibrium of a group of 
proteins belonging to the Bcl-2 family with pro-apoptotic (e.g. Bax and Bak) and anti-apoptotic (e.g. 
Bcl-2 and Mcl-1) functions (24-26). The disruption of this equilibrium leads to the mitochondrial 
outer membrane permeabilization (MOMP) with the consequent release of cytochrome-c from the 
mitochondria and activation of initiator caspase-9. The initiator caspase-9 then activates the effector 
caspase-3 that cleaves regulatory and structural molecules (e.g. poly ADP ribose polymerase, PARP), 
culminating in the death of the cell (24, 26). In this study, the activation of the intrinsic mitochondrial 
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pathway and the cleavage of pro-caspase-9 and pro-caspase-3, as well as their substrate PARP were 
observed in LC cells. In addition, the unbalance of the apoptotic pairs (Bcl-2/Bax and Mcl-1/Bak) 
towards the pro-apoptotic proteins unveils the final fate of these cells (27). In our system, the 
expression levels of pro-survival members of the Bcl-2 family (Bcl-2 and Mcl-1) decreased in a dose-
dependent manner and the pro-apoptotic proteins (Bax and Bak) increased after the treatment. In 
terms of Bcl-2, this decrease further corroborates our transcriptomic results and shows that this 
alteration is occurring at the gene level. The inhibitor of apoptosis proteins (IAPs, e.g. XIAP and 
survivin) are proteins that maintain the small leakages of cytochrome-c or small activations of death 
receptors controlled by inhibiting the initiator and effector caspases. Survivin is a member of the IAP 
family that prevents mitochondrial-dependent apoptosis through the inhibition of caspases-9 and -3 
by direct or indirect binding (24, 28). Interestingly, after compounds treatment we have seen a 
down-regulation of survivin, at both the transcript and protein levels, which also contributes to the 
triggering of the apoptotic cell death. Furthermore, using a pan-caspase inhibitor, we were able to 
significantly reverse the cytotoxic effect of our compounds. These results clearly indicate that 
compounds induce cell death through apoptosis by activating apoptosis-related proteins (caspases-9 
and -3) and decreasing the levels of anti-apoptotic proteins (Bcl-2, Mcl-1 and survivin). 
The ionophoric activity of tambjamine analogues has an impact on cellular ion homeostasis and 
intracellular pH levels (13), thus, it is feasible that their actions will produce a cellular stress. Several 
recent works have shown that unbalanced ionic homeostasis is deeply involved in ROS generation 
(29-31). In our hands, treatment with the selected compounds induced a clear ROS production and 
this could be mediated by the anion transport since our previous work has shown that these 
compounds also induce cellular acidification (13). Conversely, the non-transporter compound 
neither produced pH changes nor generated ROS. 
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The mitogen-activated protein kinases (MAPKs) are crucial signaling players in the integration of 
stress signals and their conversion to cellular responses (32). One major MAPK signaling pathway 
that is important for detecting cellular stress, including intracellular acidosis and ROS, is the p38 
MAPK cascade (32-34). The p38 MAPK-mediated apoptosis leads to caspase activation (35, 36), and 
several chemotherapeutic drugs have been shown to promote this cascade in order to produce 
apoptotic cancer cell death (36-42). Moreover, reversion of the apoptotic-mediated cell death 
produced by chemotherapeutic drugs that de-polymerize (nocodazole, vincristine and vinblastine) or 
stabilize (taxol) microtubules, was achieved by using p38 MAPK-specific inhibitors (e.g. SB203580 
and SB202190). Likewise, genotoxic agents (cisplatin and oxaliplatin) and topoisomerase II inhibitors 
(doxorubicin) were also able to activate p38 MAPK route (43, 44). Nowadays, a dual-role of this route 
is known with the action as tumor suppressor or tumor promoter largely depending on the type of 
cancer and tumor stage (45). Interestingly, our results have shown a robust p38 MAPK activation and 
using the specific p38 MAPK inhibitor, SB202190, we were able to significantly restore cell viability. 
Reversion of cell death using the pan-caspase inhibitor or the stress kinase inhibitor is very similar, 
which foresight that our compounds mediate cell death by apoptosis mainly through the p38 MAPK 
route. 
On the other hand, several transcription factors have been implicated in the regulation of both anti-
apoptotic proteins, survivin and Bcl-2: Sp1, p53, NF-κB and STAT3 (38, 46-48). While Sp1, NF-κB and 
STAT3 are generally implicated in transactivation of Bcl-2 and survivin genes, p53 was shown to be 
responsible for transcriptional repression of these genes. Moreover, these transcription factors are 
all substrates of the p38 MAPK signaling pathway (49). In fact, several articles connect p38 MAPK 
activation with a down-regulation of survivin and Bcl-2 expressions (39, 40, 50-53). Nevertheless, 
caution should be taken since other pathways are also involved in the activation/repression of these 
transcription factors and so, crosstalk with other routes is possible. Further experiments are 
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underway to understand the regulation of these genes, which have a profound impact in the fate of 
the cells by apoptosis. Our study has also shown the therapeutic effect of our compounds in a pre-
clinical setting using subcutaneous and orthotopic mouse models for LC, which indicates a good 
potential for pharmaceutical development. 
In conclusion, we have shown the cytotoxic effect of novel indole-based tambjamine analogues 
towards LC cells in vitro and in vivo. We have also identified several gene-expression profile 
alterations produced by our compounds in LC cells and have shown that the main molecular route of 
induced cell death is apoptosis, which might be activated by the p38 MAPK through ROS cellular 
stress induction. Ultimately, by understanding the mechanism of action through which these natural-
based small molecules mediate their effect in cancer cells will provide a way to improve future 
studies of drug efficacy and pharmacodynamics, as well as establish drug-response biomarkers and 
synergistic drug combinations.  
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Tables 
 
Table 1. Genes modulated after indole-based tambjamine analogues treatment. The A549 lung 
adenocarcinoma cell line was treated with the IC50 values of compounds 1 or 2 and the expression of 
84 genes related to cancer drug targets was analyzed by qRT-PCR (QIAGEN RT2 Profiler Array). Fold-
regulation values of the most altered genes are presented below. 
 Protein Name 
1  2 
Functional Gene Grouping 
6h 16h 6h 16h 
Down-regulated 
ABCC1 ATP-binding cassette, sub-family C, member 1 -1.11 -1.61 -1.48 -2.32 Drug Metabolism 
AURKA Aurora kinase A -2.53 -2.37 -2.69 -4.13 Protein Kinases 
AURKB Aurora kinase B -1.96 -2.43 -2.16 -5.03 Protein Kinases 
BCL2 B-cell CLL/lymphoma 2 -2.17 1.10 -1.83 -1.90 Apoptosis 
BIRC5 Baculoviral IAP repeat containing 5, Survivin -2.08 -2.37 -2.53 -4.72 Apoptosis 
CDC25A Cell division cycle 25 homolog A -2.30 -1.75 -3.72 -4.11 Cell Cycle 
CDK1 Cyclin-dependent kinase 1 -1.97 -2.71 -2.41 -3.94 Cell Cycle 
CDK2 Cyclin-dependent kinase 2 -1.81 -1.73 -1.24 -3.21 Cell Cycle 
ERBB3 Receptor tyrosine-protein kinase erbB-3, HER3 -2.42 -1.35 -2.81 -2.18 Growth Factors & Receptors 
ESR2 Estrogen receptor 2 -1.65 -1.20 -2.87 -1.78 Hormone Receptors 
FIGF C-fos induced growth factor, VEGFD -2.25 -1.65 -3.57 -3.74 Growth Factors & Receptors 
HDAC8 Histone deacetylase 8 -1.87 1.11 -1.52 -2.01 Histone Deacetylases 
HSP90AA1 Heat shock protein 90kDa alpha, member 1 -1.84 -1.62 -1.43 -2.47 Heat Shock Proteins 
IGF1 Insulin-like growth factor 1, Somatomedin C -4.89 -17.47 -3.48 -42.18 Growth Factors & Receptors 
NTN3 Netrin 3 -1.81 -2.11 -2.85 -1.17 Structural Protein 
PARP2 Poly (ADP-ribose) polymerase 2 -1.29 -1.63 -1.63 -2.20 Poly ADP-Ribose Polymerases 
PDGFRA Platelet-derived growth factor receptor alpha -3.55 -1.59 1.10 -2.48 Growth Factors & Receptors 
PLK1 Polo-like kinase 1 -2.24 -2.46 -2.36 -4.13 Protein Kinases 
PLK4 Polo-like kinase 4 -1.36 -2.51 -1.20 -2.02 Protein Kinases 
TOP2A Topoisomerase (DNA) II alpha 170kDa -2.06 -2.78 -2.09 -4.30 Topoisomerases, Type II 
              
Up-regulated 
CTSL1 Cathepsin L1 1.30 1.92 2.03 2.07 Cathepsins 
CTSS Cathepsin S 1.24 2.69 1.71 2.08 Cathepsins 
HSP90B1 Heat shock protein 90kDa beta, member 1 2.00 1.95 1.63 1.97 Heat Shock Proteins 
NFKB1 Nuclear factor NF-kappa-B p105 subunit 3.88 1.23 3.14 -1.01 Transcription Factors 
PRKCE Protein kinase C, epsilon 1.52 -1.04 2.53 1.95 Protein Kinases 
PTGS2 Prostaglandin-endoperoxide synthase 2, COX-2 6.46 -1.23 19.29 2.90 Drug Metabolism 
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Figure Legends 
 
Figure 1. Effect of indole-based tambjamine analogues on cell survival. a) Single point screening of 
synthetic tambjamine analogues 1-11 (10 µM) on a panel of LC cell lines (A549, DMS53, SW900 and 
H460). b) IC50 values of selected compounds (1 and 2) on LC cell lines and LC patient-derived primary 
cultures (PC#8 and PC#13). For comparison purposes, cisplatin (CDDP) was used as the standard 
clinical chemotherapeutic agent. Viability was measured using the MTT assay after 24 hours of 
treatment. Results were obtained from at least three independent experiments, and bar represents 
the mean ± S.D. 
 
Figure 2. Indole-based tambjamine analogues effect on cellular signaling pathways. A directed-
network of differentially expressed genes after compounds 1 or 2 treatment in A549 cells was 
constructed from the RT-PCR array results and data extracted from Gene Network Central (GNC-
Pro). 
 
Figure 3. Analysis of the apoptotic pathway after indole-based tambjamine analogues exposure. a) 
After 24 hours treatment with the IC25, IC50 and IC75 values of compounds 1 or 2, the expression of 
several apoptotic markers was analyzed by Western blot in A549 cell line. b, c) Bcl-2 family protein 
complexes (Bak/Mcl-1 and Bax/Bcl-2, respectively) ratios are represented in bar graphs. d) A549 cells 
were treated with 20 µM of Z-VAD-FMK for 2 hours followed by compound 1 or 2 for 6 hours. Cell 
viability was measured using the flow cytometry based MUSE™ Cell Analyzer Kit. Results were 
obtained from at least three independent experiments. Bars represent the mean ± S.D. Statistically 
significant results are indicated as *p < 0.05, **p < 0.01 and ***p < 0.001  
 
Figure 4. Indole-based tambjamine analogues induce ROS, causing cellular stress by p38 MAPK 
activation. a) A549 cells were treated with compounds 1, 2 or 3 (negative control) for 6 hours or with 
TBHP (positive control) for 2 hours. ROS formation was measured using the flow cytometry based 
MUSE™ Oxidative Stress kit. b) Phosphorylation levels of the stress kinase p38 MAPK were assessed 
by Western blot in A549 cells exposed to the IC25, IC50 and IC75 values of compounds 1, 2 or 3 for 24 
h. c) A549 cells were treated with 30 µM of SB20219 for 2 hours followed by compounds 1 or 2 for 6 
hours. Cell viability was measured using the flow cytometry based MUSE™ Cell Analyzer Kit. Results 
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were obtained from at least three independent experiments. Bars represent the mean ± S.D. 
Statistically significant results are indicated as *p < 0.05, **p < 0.01 and ***p < 0.001. 
 
Figure 5. Therapeutic effect of indole-based tambjamine-analogues in LC in vivo mouse models. a) 
Growth curve of subcutaneous tumor volumes after compound treatment show significantly 
differences between compound 2 vs control. b) The weight of subcutaneous tumors compared with 
control animals is significantly lower after compound 2 treatment. c) Compound 2 treatment reduce 
significantly the tumor weight in orthotopic DMS53 mouse xenografts model. Statistical analysis was 
performed using the nonparametric tests. *p <  0.05 and **p  <  0.01. d) Representative illustrations 
of liver and kidney histology using hematoxilin-eosin staining, at 100x and 400x magnifications (scale 
bars correspond to 200 µm and 50 µm, respectively). Histopathological examination of mice liver and 
kidney detected no obvious pathological changes after compound 1 or 2 treatment. 
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